ReviewFrontiers in nutrition2025
Roles of zinc and zinc transporters in development, progression, and treatment of inflammatory bowel disease (IBD).
Review in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Beyond Serum Zinc: Expanding the Understanding of Mucosal Zinc Homeostasis in Ulcerative Colitis.Journal of gastroenterology and hepatology · 2026Article
- Diet and Gut Microbiota in Inflammatory Bowel Disease: A Clinical and Nutritional Perspective.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Zinc gluconate ameliorates antibiotics/PGN-induced intestinal injury via modulating the gut barrier, macrophages immunity and gut microbiota.Frontiers in microbiology · 2026Article
- Ferroptosis in diabetic retinopathy: from pathogenic mechanisms to translational prospects.Frontiers in endocrinology · 2026Review
- Zinc Deficiency Among Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.Cureus · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The inflammatory bowel diseases (IBD), including Crohn's Disease and Ulcerative Colitis, are chronic, incurable disorders of the gastrointestinal tract. These multifactorial diseases pose an enormous burden on patients, clinicians, and public health systems worldwide. Zinc (Zn) is an essential micronutrient that is required for a wide variety of functions critical to maintaining gastrointestinal health. Zn homeostasis is facilitated by the SLC39/ZIP and SLC30/ZnT families of solute carrier proteins, which collectively distribute Zn with subcellular specificity. Disruptions in Zn homeostasis can have substantial impacts on health, as recent years have seen Zn transporters become increasingly recognized for their importance in health and disease. Although dietary Zn deficiency is rare in the United States, Zn deficiency is common among IBD patients. Disruptions in Zn homeostasis have also been shown to play a role in the progression of IBD. Despite these links, Zn supplementation trials in IBD have shown inconsistent results. This review focuses on the role of Zn and Zn transporters in the development, progression, and treatment of IBD, as well as discussing the challenges and potentially promising future of the study of Zn and Zn transporters in precision health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.